Australia Health

Vitura Health (ASX:VIT) has appointed finance executive Andrew Cook as its CFO. Based in Queensland, Cook is expected to assume the role in the third quarter of FY26.

Mesoblast (ASX:MSB), a global leader in allogeneic cellular therapies for inflammatory diseases, reported a 60% increase in Ryoncil (remestemcel-L-rknd) sales, generating US$35.1 million in gross revenue for the December 2025 quarter.

Hydrix (ASX:HYD) has announced that its wholly owned subsidiary, Hydrix Services, has entered a contract with SynCardia Systems, a subsidiary of Picard Medical, to commence the initial development phase of SynCardia's next-generation fully implantable total artificial heart, known as the Emperor.

Alcidion Group (ASX:ALC) has been selected as the preferred supplier for University Hospitals Sussex NHS Foundation Trust's new electronic patient record system.

Syntara (ASX:SNT), a clinical-stage drug development company, has announced the completion of patient recruitment for its Phase 2, randomised, double-blind, placebo-controlled trial of SNT-4728.

Nyrada (ASX:NYR), a clinical-stage biotechnology company developing TRPC ion channel inhibitors, has received approval from the Human Research Ethics Committee to commence its Phase 2a clinical trial of Xolatryp

Australian-Singaporean regenerative medicine company Osteopore (ASX: OSX) has secured an exclusive licensing agreement with Accelerate for a pioneering Heparan Sulphate bioactive technology platform.

LTR Pharma (ASX:LTP) announced that its Phase 1 clinical study of SPONTAN nasal spray has been accepted for podium presentation at the World Meeting on Sexual Medicine 2026.

Australian antiviral developer Island Pharmaceuticals (ASX:ILA) has been granted US Patent Number 12,508,266 by the US Patent and Trademark Office for the use of Galidesivir.

Neuren Pharmaceuticals (ASX:NEU) announced that results from its Phase 2 clinical trial of NNZ-2591 in children and adolescents with Phelan-McDermid syndrome have been published in Neurology Genetics

UC San Diego Health has commenced clinical use of 4DMedical’s (ASX:4DX) advanced respiratory imaging technology, CT:VQ.

Nexsen (ASX:NXN) has taken a major step toward US market entry with the commencement of engagement with the US Food and Drug Administration for its rapid Group B Streptococcus point-of-care diagnostic.